UniProt genomic mapping for deciphering functional effects of missense variants
暂无分享,去创建一个
[1] Alan Bridge,et al. An enhanced workflow for variant interpretation in UniProtKB/Swiss-Prot improves consistency and reuse in ClinVar , 2019, Database J. Biol. Databases Curation.
[2] Yuan Tian,et al. A Bayesian framework for efficient and accurate variant prediction , 2018, PloS one.
[3] S. Boca,et al. Future of Evidence Synthesis in Precision Oncology: Between Systematic Reviews and Biocuration. , 2018, JCO precision oncology.
[4] Chunling Hu,et al. Assessment of the Clinical Relevance of BRCA2 Missense Variants by Functional and Computational Approaches. , 2018, American journal of human genetics.
[5] Bruce D. Gelb,et al. ClinGen’s RASopathy Expert Panel Consensus Methods for Variant Interpretation , 2018, Genetics in Medicine.
[6] R. Nussbaum,et al. Modeling the ACMG/AMP Variant Classification Guidelines as a Bayesian Classification Framework , 2018, Genetics in Medicine.
[7] Chunlei Liu,et al. ClinVar: improving access to variant interpretations and supporting evidence , 2017, Nucleic Acids Res..
[8] Subha Madhavan,et al. ClinGen Cancer Somatic Working Group - Standardizing and democratizing access to cancer molecular diagnostic data to drive translational research , 2018, PSB.
[9] Lily Hoffman-Andrews. The known unknown: the challenges of genetic variants of uncertain significance in clinical practice , 2017, Journal of law and the biosciences.
[10] Daniel J. Park,et al. Variant effect prediction tools assessed using independent, functional assay-based datasets: implications for discovery and diagnostics , 2017, Human Genomics.
[11] Keith Nykamp,et al. Sherloc: a comprehensive refinement of the ACMG–AMP variant classification criteria , 2017, Genetics in Medicine.
[12] Matthew S. Lebo,et al. Using large sequencing data sets to refine intragenic disease regions and prioritize clinical variant interpretation , 2016, Genetics in Medicine.
[13] Maria Jesus Martin,et al. The Proteins API: accessing key integrated protein and genome information , 2017, Nucleic Acids Res..
[14] Alessandro Vullo,et al. Ensembl 2017 , 2016, Nucleic Acids Res..
[15] D. Karolchik,et al. The UCSC Genome Browser database: 2017 update , 2016, Nucleic Acids Res..
[16] Joshua L. Deignan,et al. A survey of current practices for genomic sequencing test interpretation and reporting processes in US laboratories , 2016, Genetics in Medicine.
[17] D. MacArthur,et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples , 2016, Genetics in Medicine.
[18] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[19] Subha Madhavan,et al. Somatic cancer variant curation and harmonization through consensus minimum variant level data , 2016, Genome Medicine.
[20] Trevor Hastie,et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. , 2016, American journal of human genetics.
[21] Peter Szolovits,et al. Genetic Misdiagnoses and the Potential for Health Disparities. , 2016, The New England journal of medicine.
[22] Levi C. T. Pierce,et al. Deep sequencing of 10,000 human genomes , 2016, Proceedings of the National Academy of Sciences.
[23] Matthew S. Lebo,et al. Performance of ACMG-AMP Variant-Interpretation Guidelines among Nine Laboratories in the Clinical Sequencing Exploratory Research Consortium. , 2016, American journal of human genetics.
[24] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, Genome Biology.
[25] Daniel R. Zerbino,et al. Ensembl 2016 , 2015, Nucleic Acids Res..
[26] Glenn A. Maston,et al. A Standardized DNA Variant Scoring System for Pathogenicity Assessments in Mendelian Disorders , 2015, Human mutation.
[27] H. Rehm,et al. Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.
[28] Colin Campbell,et al. An integrative approach to predicting the functional effects of non-coding and coding sequence variation , 2015, Bioinform..
[29] Elisabeth Coudert,et al. HAMAP in 2015: updates to the protein family classification and annotation system , 2014, Nucleic Acids Res..
[30] Jerven T. Bolleman,et al. Genetic Variations and Diseases in UniProtKB/Swiss-Prot: The Ins and Outs of Expert Manual Curation , 2014, Human mutation.
[31] D. G. MacArthur,et al. Guidelines for investigating causality of sequence variants in human disease , 2014, Nature.
[32] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[33] Deanna M. Church,et al. ClinVar: public archive of relationships among sequence variation and human phenotype , 2013, Nucleic Acids Res..
[34] Ting Wang,et al. Track data hubs enable visualization of user-defined genome-wide annotations on the UCSC Genome Browser , 2013, Bioinform..
[35] Lora J. H. Bean,et al. Free the Data: One Laboratory's Approach to Knowledge‐Based Genomic Variant Classification and Preparation for EMR Integration of Genomic Data , 2013, Human mutation.
[36] P. Padakannaya,et al. Copy number variation-based polymorphism in a new pseudoautosomal region 3 (PAR3) of a human X-chromosome-transposed region (XTR) in the Y chromosome , 2013, Functional & Integrative Genomics.
[37] Xiao-xia Liu,et al. [Genetic and clinical study of three Chinese pedigrees with Fabry disease]. , 2013, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics.
[38] I. Adzhubei,et al. Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.
[39] Tom R. Gaunt,et al. Predicting the Functional, Molecular, and Phenotypic Consequences of Amino Acid Substitutions using Hidden Markov Models , 2012, Human mutation.
[40] R. Altman,et al. Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.
[41] Rachael P. Huntley,et al. The UniProt-GO Annotation database in 2011 , 2011, Nucleic Acids Res..
[42] A. Mehta,et al. Functional analysis of variant lysosomal acid glycosidases of Anderson-Fabry and Pompe disease in a human embryonic kidney epithelial cell line (HEK 293 T) , 2012, Journal of Inherited Metabolic Disease.
[43] Yusuke Nakamura,et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. , 2011, The Journal of infectious diseases.
[44] Yusuke Nakamura,et al. Common genetic polymorphism of ITPA gene affects ribavirin‐induced anemia and effect of peg‐interferon plus ribavirin therapy , 2011, Journal of medical virology.
[45] D. Lockhart,et al. A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease , 2011, Human mutation.
[46] David McHugh,et al. Genetics in Medicine : Official Journal of the American College of Medical Genetics , 2011 .
[47] Cathy H. Wu,et al. Structure-guided rule-based annotation of protein functional sites in UniProt knowledgebase. , 2011, Methods in molecular biology.
[48] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[49] Galt P. Barber,et al. BigWig and BigBed: enabling browsing of large distributed datasets , 2010, Bioinform..
[50] Xinning Jiang,et al. Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry. , 2009, Journal of proteome research.
[51] R. Schiffmann. Fabry disease. , 2009, Pharmacology & therapeutics.
[52] A. Spurdle,et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results , 2008, Human mutation.
[53] S. Ishii,et al. Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin. , 2007, The Biochemical journal.
[54] B. Morris,et al. The Human Pseudoautosomal Region (PAR): Origin, Function and Future. , 2007, Current Genomics.
[55] Andreas Prlic,et al. Ensembl 2007 , 2006, Nucleic Acids Res..
[56] R. Desnick,et al. Detection of α‐galactosidase a mutations causing fabry disease by denaturing high performance liquid chromatography , 2005 .
[57] K. Mills,et al. Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease , 2005, Journal of Inherited Metabolic Disease.
[58] R. Desnick,et al. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography. , 2005, Human mutation.
[59] F. Collins,et al. The MLH1 D132H variant is associated with susceptibility to sporadic colorectal cancer , 2004, Nature Genetics.
[60] D. Garboczi,et al. The molecular defect leading to Fabry disease: structure of human alpha-galactosidase. , 2004, Journal of molecular biology.
[61] S. Amladi,et al. Online Mendelian Inheritance in Man 'OMIM'. , 2003, Indian journal of dermatology, venereology and leprology.
[62] Huawei Qiu,et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. , 2003, Glycobiology.
[63] S. Kornfeld,et al. Mannose 6-phosphate receptors: new twists in the tale , 2003, Nature Reviews Molecular Cell Biology.
[64] Jim Kent,et al. autoSQL and autoXML: code generators from the genome project , 2002 .
[65] Tom H. Pringle,et al. The human genome browser at UCSC. , 2002, Genome research.
[66] B. Winchester,et al. Fabry disease: 20 novel GLA mutations in 35 families , 2001, Human mutation.
[67] S. Younkin,et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation , 2001, Nature Neuroscience.
[68] H. Vanderstichele,et al. Nonfibrillar diffuse amyloid deposition due to a gamma(42)-secretase site mutation points to an essential role for N-truncated A beta(42) in Alzheimer's disease. , 2000, Human molecular genetics.
[69] C. Masters,et al. Novel Leu723Pro amyloid precursor protein mutation increases amyloid β42(43) peptide levels and induces apoptosis , 2000, Annals of neurology.
[70] D. Valle,et al. Online Mendelian Inheritance In Man (OMIM) , 2000, Human mutation.
[71] C. Eng,et al. Twenty Novel Mutations in the α-Galactosidase A Gene Causing Fabry Disease , 1999, Molecular medicine.
[72] L. Poenaru,et al. Fabry disease: identification of novel alpha-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. , 1999, Biochemical and biophysical research communications.
[73] D. Campion,et al. Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s disease , 1999 .
[74] D. Campion,et al. Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 --> Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[75] A. Hofman,et al. Presenile Alzheimer dementia characterized by amyloid angiopathy and large amyloid core type senile plaques in the APP 692Ala→Gly mutation , 1998, Acta Neuropathologica.
[76] R. Desnick,et al. Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility. , 1998, The Biochemical journal.
[77] D. Selkoe. The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. , 1998, Trends in cell biology.
[78] R. Froissart,et al. Mutation analysis in 11 French patients with Fabry disease , 1998, Human mutation.
[79] J. Hardy,et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). , 1997, Human molecular genetics.
[80] R. Wevers,et al. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the alpha-galactosidase A gene. , 1996, Journal of medical genetics.
[81] J. Rashbass. Online Mendelian Inheritance in Man. , 1995, Trends in genetics : TIG.
[82] C. Eng,et al. Molecular basis of fabry disease: Mutations and polymorphisms in the human α‐galactosidase A gene , 1994 .
[83] C. Eng,et al. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. , 1994, Human mutation.
[84] A. Roses,et al. Characterization of Amyloid Familial β-Peptide in Familial Alzheimer′s Disease with APP717 Mutations , 1993 .
[85] C. Eng,et al. Nature and frequency of mutations in the alpha-galactosidase A gene that cause Fabry disease. , 1993, American journal of human genetics.
[86] S. Malcolm,et al. Mutation analysis in patients with the typical form of Anderson-Fabry disease. , 1993, Human molecular genetics.
[87] R. Denman,et al. A system for studying the effect(s) of familial Alzheimer disease mutations on the processing of the beta-amyloid peptide precursor. , 1993, Biochemical and biophysical research communications.
[88] R. Loewenstein,et al. A Survey of Current Practices , 1993 .
[89] B. Ghetti,et al. Characterization of amyloid fibril beta-peptide in familial Alzheimer's disease with APP717 mutations. , 1993, Biochemical and biophysical research communications.
[90] B. Winblad,et al. A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.
[91] A. Hofman,et al. Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β–amyloid precursor protein gene , 1992, Nature Genetics.
[92] J. Hardy,et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.
[93] B. Ghetti,et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.
[94] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[95] V. McKusick. Mendelian inheritance in man , 1971 .
[96] B. Migeon,et al. Genetic Inactivation of the α-Galactosidase Locus in Carriers of Fabry's Disease , 1970, Science.
[97] B. Migeon,et al. Genetic inactivation of the alpha-galactosidase locus in carriers of Fabry's disease. , 1970, Science.